Jagsonpal Pharma

Jagsonpal Pharma commenced FY26 on a robust note, reporting a 23% year-on-year revenue growth to ₹75.5 crores. This growth was primarily attributed to strong brand equity and a focused marketing push. The company achieved an 80 bps expansion in gross margins, reaching 64.4%, and saw its Operating EBITDA before ESOP increase by 24% to ₹157 million, with margins at 20.8%. Net profit doubled to ₹108 million, reflecting a 560 bps improvement in net margins to 14.3%.

The company disclosed the termination of its CFO, Mr. Sachin Jain, on July 8, 2025, within his probation period. The termination was due to acts of misbehavior, misconduct, and misrepresentation. Management emphasized its commitment to ethics and governance, stating that the Board of Directors acted quickly and decisively to safeguard the company's values.

Jagsonpal Pharma ended the quarter with a healthy cash balance of ₹161 crores, an increase of ₹153 million from the previous quarter, and generates approximately ₹5 crores in cash monthly. The company's inorganic growth strategy is focused on India and subchronic therapeutic segments, open to both brand and business acquisitions. Management stated there is no pressure to deploy cash, prioritizing strategic fit and pricing, and indicated that funds not used for M&A would be returned to shareholders.

The company is focusing on 'skilling up' its field force rather than merely increasing headcount, aiming to improve productivity. MR productivity has already seen a 10% improvement, with a long-term target of ₹3-3.5 lakhs per month. Initiatives include better retention, training, and incentive structures, acknowledging field force attrition as an industry-wide challenge.

Jagsonpal Pharma acknowledged significant pricing pressure on its Dydrogestorone molecule, which has seen sales decline from a peak of ₹40 crores to ₹10 crores. The company maintains its pricing strategy, even if it means losing market share in this specific molecule, as it prioritizes quality and ethics over aggressive competition in certain segments.

The company reiterated its full-year guidance of 15% overall growth and 100-150 bps EBITDA margin expansion. While Q1 did not show margin expansion due to higher marketing investments, management expects improvements from Q2 onwards. Organic growth for Q1 was 9-10%, with a forward-looking organic growth target of 12-14%.

Jagsonpal Pharma detailed its MySakhi CSR initiative, which focuses on women's health and education. The program includes constructing physical amenities like toilets and sanitary pad dispensing machines in schools and colleges, and an educational platform (MySakhi.in) offering webinars and resources on women's health topics, including menstrual hygiene and menopause.